Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 7/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1470954 | 0.81 | HTR1A (0.57) | HTR1ADRD2ADRA1DHTR1BADRA1A | |
| SCHEMBL1471529 | 0.81 | HTR1A (0.64) | PRMT6HTR1ATRPA1ADRA1DADRA1A | |
| SCHEMBL1471029 | 0.72 | HTR1A (0.59) | HTR1ADRD2ADRA1DHTR1BADRA1A | |
| SCHEMBL1470711 | 0.69 | HTR1A (0.58) | HTR1ADRD2ADRA1DHTR1BADRA1A | |
| Formaldehyde SCHEMBL1471574 | 0.68 | PRMT6 (0.50) | PRMT6TRPA1AGXT | |
| SCHEMBL1471422 | 0.68 | PRMT6 (0.53) | PRMT6TRPA1DRD2AGXT | |
| SCHEMBL1470936 | 0.67 | HTR1A (0.56) | HTR1ADRD2ADRA1DHTR1BADRA1A | |
| SCHEMBL1036548 | 0.66 | PRMT6 (1.00) | PRMT6TRPA1AGXT | |
| SCHEMBL30228501 | 0.66 | PRMT6 (0.62) | PRMT6TRPA1AGXTHCRTR1HCRTR2 | |
| SCHEMBL19595393 | 0.66 | PRMT6 (0.67) | PRMT6TRPA1AGXTHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915420-B2 | Aryl piperidine amides | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20080009521-A1 | Aryl Piperidine Amides | HUANG CHARLES Q | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009521-A1 | Aryl Piperidine Amides | BDNF, NTRK2, OPRL1 | PRMT6 1303/4885HTR1A 286/4885TRPA1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.